Background Targeted therapy has revolutionized cancer treatment, greatly improving patient
outcomes and quality of life. Lung cancer, specifically non-small cell lung cancer, is …

The development of covalent inhibitors against KRAS G12C represents a major milestone in
treatment of RAS-driven cancers, especially in non-small cell lung cancer (NSCLC), where …

Background KRAS mutations are the most frequent oncogenic aberration in lung
adenocarcinoma. KRAS mutant isoforms differentially shape tumour biology and influence …

BACKGROUND The KRAS proto-oncogene is among the most frequently mutated genes in
cancer, yet for 40 years it remained an elusive therapeutic target. Recently, allosteric …

Purpose: KRAS is among the most commonly mutated oncogene in cancer including non–
small cell lung cancer (NSCLC). In early clinical trials, inhibitors targeting G12C-mutant …

Simple Summary A better understanding of the role of KRAS and its different mutations has
led to the development of specific small-molecule inhibitors able to target KRAS G12C, an …

Abstract Purpose of Review Although the recent development of direct KRASG12C inhibitors
(G12Ci) has improved outcomes in KRAS mutant cancers, responses occur only in a fraction …

Approximately 15% of all cancer patients harbor mutated KRAS. Direct inhibitors of KRAS
have now been generated and are beginning to make progress through clinical trials. These …

Background. KRASG12C inhibitors have shown promising efficacy in early clinical trials, but
drug resistance compromises their long‐term benefits. Therefore, it is critical to understand …

The clinical approvals of KRAS G12C inhibitors have been a revolutionary advance in
precision oncology, but response rates are often modest. To improve patient selection, we …